El Ouali Sara, Achkar Jean-Paul, Lashner Bret, Regueiro Miguel
Department of Gastroenterology & Hepatology, Digestive Disease Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, UAE
Department of Gastroenterology, Hepatology & Nutrition, Digestive Disease & Surgery Institute, Cleveland Clinic, Cleveland, OH.
Cleve Clin J Med. 2021 Feb 17. doi: 10.3949/ccjm.87a.ccc049.
Gastrointestinal (GI) symptoms are seen in patients with COVID-19. The prevalence could be as high as 50%, but most studies show ranges from 16% to 33%. Presenting with GI symptoms increases the risk of testing positive for SARs-CoV-2. Approximately 50% of patients with COVID-19 have detectable virus in their stool. Having GI symptoms has been associated with more severe disease. Management of GI symptoms is mainly supportive. Healthcare providers should be aware of the GI manifestations of COVID-19 and perform SARS-CoV-2 testing for patients presenting with digestive changes, especially in those with respiratory symptoms.
新冠肺炎患者会出现胃肠道（GI）症状。其患病率可能高达50%，但大多数研究显示在16%至33%之间。出现胃肠道症状会增加感染新型冠状病毒2（SARS-CoV-2）检测呈阳性的风险。约50%的新冠肺炎患者粪便中可检测到病毒。出现胃肠道症状与病情更严重有关。胃肠道症状的管理主要是支持性的。医疗服务提供者应了解新冠肺炎的胃肠道表现，并对出现消化系统变化的患者进行新型冠状病毒2检测，尤其是有呼吸道症状的患者。
